VIDEO: Can venetoclax plus obinutuzumab retreatment have its ‘ReVenG’ in relapsed CLL?
In a video interview with Healio, Matthew S. Davids, MD, MMSc, of Dana-Farber Cancer Institute, discussed the ReVenG trial, which was presented at ASH Annual Meeting and Exposition.
The trial hopes to determine the feasibility of venetoclax plus obinutuzumab retreatment in patients with chronic lymphocytic leukemia initially treated with this same regimen who went into remission and then relapsed, according to Davids.
“This is a key question in the field right now. That regimen’s been approved for a couple of years. We’re just starting to see some patients now relapsing, and although there are other good options in CLL... there is an attractive benefit potentially to reusing the same regimen, especially if the patient tolerated it well before,” Davids told Healio. “Hopefully we’ll learn a lot about the efficacy of retreatment with venetoclax in the front-line setting.”
Collapse
Davids, MS. Abstract 2634. Presented at: ASH Annual Meeting and Exposition; Dec. 11-14, 2021; Atlanta.